Search results
Showing 736 to 750 of 1259 results for pathway
Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.
months. There are no clinical trials to define the optimal rehabilitation pathway following hip fracture for these people and therefore...
NICE has developed a medtech innovation briefing (MIB) on Smartinhaler for asthma .
MR-proADM test for use with clinical deterioration scores in cases of suspected infection (MIB195)
NICE has developed a medtech innovation briefing (MIB) on the MR-proADM test for use with clinical deterioration scores in cases of suspected infection .
Bortezomib for previously untreated mantle cell lymphoma (TA370)
Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.
Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)
Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults.
The NICE public health guidance development process (third edition) (PMG5)
This manual describes how public health guidance is produced, and explains the stages of guidance development, the different activities, roles and responsibilities of different groups of people involved at different stages
This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used
NICE has developed a medtech innovation briefing (MIB) on ReStore Soft Exo-Suit for gait rehabilitation .
NICE has developed a medtech innovation briefing (MIB) on Colli-Pee for first void urine collection .
NICE has developed a medtech innovation briefing (MIB) on TopClosure Tension Relief System for wound closure .
Evidence-based recommendations on the RD-100i OSNA system and Metasin test for detecting sentinel lymph node metastases in people having breast cancer surgery.
Evidence-based recommendations on efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over.
the recommendations. As there was limited evidence on the most effective pathway for excluding clinically significant progression of...
Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.